120 related articles for article (PubMed ID: 2026357)
1. Human ovarian cancer cell lines resistant to cisplatin, doxorubicin, and L-phenylalanine mustard are sensitive to delta 7-prostaglandin A1 and delta 12-prostaglandin J2.
Sasaki H; Takada K; Terashima Y; Ekimoto H; Takahashi K; Tsuruo T; Fukushima M
Gynecol Oncol; 1991 Apr; 41(1):36-40. PubMed ID: 2026357
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of delta 7-prostaglandin A1 and delta 12-prostaglandin J2 in vitro and in vivo.
Kato T; Fukushima M; Kurozumi S; Noyori R
Cancer Res; 1986 Jul; 46(7):3538-42. PubMed ID: 3708585
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of 13,14-dihydro-15-deoxy-delta7-prostaglandin-A1-methyl ester integrated into lipid microspheres against human ovarian carcinoma cells resistant to cisplatin in vivo.
Sasaki H; Niimi S; Akiyama M; Tanaka T; Hazato A; Kurozumi S; Fukushima S; Fukushima M
Cancer Res; 1999 Aug; 59(16):3919-22. PubMed ID: 10463583
[TBL] [Abstract][Full Text] [Related]
4. Antiproliferative effect of silybin on gynaecological malignancies: synergism with cisplatin and doxorubicin.
Scambia G; De Vincenzo R; Ranelletti FO; Panici PB; Ferrandina G; D'Agostino G; Fattorossi A; Bombardelli E; Mancuso S
Eur J Cancer; 1996 May; 32A(5):877-82. PubMed ID: 9081370
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant effects of antineoplastic prostaglandins to cisplatin in nude mice bearing human ovarian cancer cells.
Kikuchi Y; Kita T; Miyauchi M; Hirata J; Sasa H; Nagata I; Fukushima M
J Cancer Res Clin Oncol; 1992; 118(6):453-7. PubMed ID: 1618893
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory properties of antitumor prostaglandins against topoisomerases.
Suzuki K; Uyeda M
Biosci Biotechnol Biochem; 2002 Aug; 66(8):1706-12. PubMed ID: 12353631
[TBL] [Abstract][Full Text] [Related]
7. The effects of cyclosporin A on the lysis of ovarian cancer cells by cisplatin or adriamycin.
Mutch DG; Herzog TJ; Chen CA; Collins JL
Gynecol Oncol; 1992 Oct; 47(1):28-33. PubMed ID: 1427396
[TBL] [Abstract][Full Text] [Related]
8. Prostaglandins in the treatment of cancer.
Sasaki H; Fukushima M
Anticancer Drugs; 1994 Apr; 5(2):131-8. PubMed ID: 8049495
[TBL] [Abstract][Full Text] [Related]
9. Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines.
Strumberg D; Harstrick A; Doll K; Hoffmann B; Seeber S
Anticancer Drugs; 1996 Jun; 7(4):415-21. PubMed ID: 8826610
[TBL] [Abstract][Full Text] [Related]
10. Synergy is documented in vitro with low-dose recombinant tumor necrosis factor, cisplatin, and doxorubicin in ovarian cancer cells.
Bonavida B; Tsuchitani T; Zighelboim J; Berek JS
Gynecol Oncol; 1990 Sep; 38(3):333-9. PubMed ID: 2227544
[TBL] [Abstract][Full Text] [Related]
11. delta 12-Prostaglandin-J2 is cytotoxic in human malignancies and synergizes with both cisplatin and radiation.
McClay EF; Winski PJ; Jones JA; Jennerette J; Gattoni-Celli S
Cancer Res; 1996 Sep; 56(17):3866-9. PubMed ID: 8752147
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of antitumour activity of cisplatin by N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine. HCl in human ovarian cancer cells with intrinsic or acquired resistance to cisplatin.
Kudoh K; Kikuchi Y; Hiramatsu H; Hirata J; Yamamoto K; Kita T; Nagata I
Eur J Cancer; 1997 Jan; 33(1):122-8. PubMed ID: 9071911
[TBL] [Abstract][Full Text] [Related]
13. Novel phosphonium salts display in vitro and in vivo cytotoxic activity against human ovarian cancer cell lines.
Manetta A; Gamboa G; Nasseri A; Podnos YD; Emma D; Dorion G; Rawlings L; Carpenter PM; Bustamante A; Patel J; Rideout D
Gynecol Oncol; 1996 Feb; 60(2):203-12. PubMed ID: 8631539
[TBL] [Abstract][Full Text] [Related]
14. Effects of a new antioestrogen, idoxifene, on cisplatin- and doxorubicin-sensitive and -resistant human ovarian carcinoma cell lines.
Sharp SY; Rowlands MG; Jarman M; Kelland LR
Br J Cancer; 1994 Sep; 70(3):409-14. PubMed ID: 8080723
[TBL] [Abstract][Full Text] [Related]
15. Augmentation of antiproliferative activity of recombinant human tumor necrosis factor by delta 12-prostaglandin J2.
Mori H; Takada Y; Kondoh H; Tamaya T
J Biol Response Mod; 1990 Apr; 9(2):260-3. PubMed ID: 2341865
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo characterisation of low-resistant mouse reticulosarcoma (M5076) sublines obtained after pulse and continuous exposure to cisplatin.
Belvedere G; Imperatori L; Damia G; Tagliabue G; Meijer C; de Vries EG; D'Incalci M
Eur J Cancer; 1996 Oct; 32A(11):2011-8. PubMed ID: 8943689
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of resistance to cisplatin in a human ovarian-carcinoma cell line selected for resistance to doxorubicin: possible role of p53.
Vikhanskaya F; Clerico L; Valenti M; Stanzione MS; Broggini M; Parodi S; Russo P
Int J Cancer; 1997 Jul; 72(1):155-9. PubMed ID: 9212237
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of inhibition of herpes simplex virus replication by delta 7-prostaglandin A1 and delta 12-prostaglandin J2.
Yamamoto N; Fukushima M; Tsurumi T; Maeno K; Nishiyama Y
Biochem Biophys Res Commun; 1987 Aug; 146(3):1425-31. PubMed ID: 3040001
[TBL] [Abstract][Full Text] [Related]
19. Bisdioxopiperazine, (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF 187), enhances the antiproliferative effect of cisplatin on human ovarian cancer cells.
Scambia G; Della Bitta R; Benedetti Panici P; De Vincenzo R; Contu G; Ercoli A; Bonanno G; Pierelli L; Mancuso S
Gynecol Oncol; 1995 Apr; 57(1):16-22. PubMed ID: 7705696
[TBL] [Abstract][Full Text] [Related]
20. Correlation of chemosensitivity to anticancer drugs and telomere length, telomerase activity and telomerase RNA expression in human ovarian cancer cells.
Kiyozuka Y; Yamamoto D; Yang J; Uemura Y; Senzaki H; Adachi S; Tsubura A
Anticancer Res; 2000; 20(1A):203-12. PubMed ID: 10769656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
